A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors

Haemophilia

Volumn 11, Issue 3, 2005, Pages 261-269

  Putnam, K G ^a,b   Bohn, R L ^a,b   Ewenstein, B M ^a,b   Winkelmayer, W C ^a,b   Avorn, Jerry ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Activated prothrombin complex complexes; Costs and cost analysis; Decision analysis; Factor VIIa; Factor VIII; Hemophilia; Inhibitors

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANTIBODY TITER; ARTICLE; BLEEDING; CONSENSUS; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; DECISION MAKING; DRUG DOSE REGIMEN; HEMARTHROSIS; HEMOPHILIA A; MEDICAL SPECIALIST; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; UNITED STATES;

AUTOANTIBODIES; BLOOD COAGULATION FACTORS; CHILD; DRUG ADMINISTRATION SCHEDULE; FACTOR VII; FACTOR VIII; HEALTH CARE COSTS; HEMARTHROSIS; HEMOPHILIA A; HOME CARE SERVICES; HUMANS; MODELS, ECONOMIC; RECOMBINANT PROTEINS;

EID: 19444383858     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2005.01098.x     Document Type: Article

References (24)

1. Teitel J. Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: treatment and cost considerations. Haemophilia 1999; 5(Suppl. 3): 43-49.
2. Gold M, Gold S, Weinstein ME. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press, 1996.
3. Shord S, Lindley C. Coagulation products and their uses. Am J Health System Pharm 2000; 57: 1403-20.
4. TreeAge Software Inc. Data [program], 3.5.8 version. Williamstown, MA: TreeAge Software Inc., 1988-2000.
5. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995; 311: 376-80.
6. Abshire T. Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: improved efficacy with higher dosing. Semin Hematol 2004; 41(Suppl. 1): 3-7.
7. Kulkarni R, Aledort L, Berntorp E, Brackman H, Brown D, Cohen A. Therapeutic choices for patients with hemophilia and high-titer inhibitors. Am J Hematol 2001; 67: 240-6.
8. Hedner U. Factor VIIa in the treatment of haemophilia. Blood Coagul Fibrinolysis 1990; 1: 307-17.
9. Lusher J, Giangrande P, Ewenstein B et al. Workshop 2: efficacy, safety and treatment cost considerations. Haemophilia 1997; 3(Suppl. 3): 12-23.
10. Bohn R, Avorn J, Glynn R, Choodnovskiy I, Haschemeyer R, Aledort L. Prophylactic use of factor VIII: an economic evaluation. Thromb Haemost 1998; 79: 932-7.
11. Odeyemi IAO, Guest JF. Modeling the economic impact of recombinant activated factor VII compared to activated prothrombin-complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting factors VIII and IV in the UK. 5:119. J Med Econ 2002; 5: 119-33.
12. Hind D, Llyod-Jones M, Makris M, Paisley S. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia A and inhibitors (Cochrane Review). In: The Cochrane Library, Issue 2, 2004, Chichester, UK: John Wiley & Sons, Ltd.
13. Abildgaard C, Penner J, Watson-Williams E. Antiinhibitor coagulant complex (Autoplex) for treatment of factor VIII inhibitors in hemophilia. Blood 1980; 56: 978-84.
14. Buchanan G, Kevy S. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies. Pediatrics 1978; 62: 767-74.
15. Hilgartner M, Knatterud G, and the FEIBA study group. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61: 36-40.
16. Hilgartner M, Aledort L, Andes A, Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in haemophilia patients. Transfusion 1990; 30: 626-30.
17. Lusher J, Blatt P, Penner J et al. Autoplex versus Proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood 1983; 62: 1135-8.
18. Negrier C, Goudemand J, Sultan Y et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997; 77: 1113-9.
19. Sjamsoedin L, Heijnen L, Mauser-Bunschoten E et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. New Engl J Med 1981; 305: 717-21.
20. Kantrowitz J, Lee M, McClure D, Kingdon H, Thomas W. Early experience with the use of anti-inhibitor coagulant complex to treat bleeding in hemophiliacs with inhibitors to factor VIII. Clin Ther 1987;9:405-19.
21. Key N, Aledort L, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
22. Lusher J, Roberts H, Davignon G et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia 1998; 4: 790-8.
23. Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999; 104: 22-6.
24. Shapiro A. American experience with home use of NovoSeven: recombinant factor VIIa in hemophiliacs with inhibitors. Haemostasis 1996; 26(Suppl. 1): 143-9.